Schott Ready-to-Fill Syringes in U.S.

Schott forma vitrum is developing production of ready-to-fill syringes, Schott forma 3s, in the United States, by expanding capacity at its Lebanon, PA pharmaceutical packaging facility. The company is investing $46 million to add a full line of ready-to-fill syringe products. Schott said it expects to add 125 jobs at the facility, where it also manufactures vials and dental cartridges.

The imitative will meet accelerating demand for syringes in the North American market, Schott officials said.

“The transition in the United States from single dose vials to prefilled syringes is gaining momentum,” says Christian Helbig, business development manager, pharmaceutical systems, Schott North America Inc. “The vaccine side is growing, and the biotech industry is viewing the prefilled format as a key vehicle for accommodating self-administration for home use of therapies.”

Helbig says the Lebanon facility will duplicate production processes used in St. Gallen, Switzerland, where Schott is presently expanding capacity for manufacturing glass as well as for polymer prefillable syringes. The production schedule in Lebanon will incorporate techniques including syringe washing, siliconization, nesting, and final packaging, all under cleanroom conditions.

Schott’s forma 3s format portfolio comprises luer lock, luer cone, and staked-needle configurations in sizes of 0.5 to 3 ml. The latest addition to forma 3s offerings is the launch of “The Fast Track.” a sterile standard syringe set including 4500 syringes, ready-to-use plungers, and plunger rods, with extensive documentation including functional data. Fast track will be supplied from inventory and allow customers to start work with all components in place with a two-week lead time.

Helbig says initial production in Lebanon will be in the range of 70 million pieces a year.

Schott reports that global demand for prefilled syringes is projected at an annual 8–10% for the next several years.

“Demand for syringes in the United States has grown steadily in recent years and will continue with the increasing incidence and detection of chronic diseases,” says Gary Waller, director of North American sales and marketing, Schott Pharmaceutical Packaging.

The Lebanon expansion will add to more than 500 production lines in 12 production sites worldwide that produce product including syringes, vials, ampules, and cartridges, the company said.

No votes yet